

7. (Amended) A formulation according to claim 1 for intravenous use.

8. (Amended) A formulation according to claim 1 wherein the estramustine phosphate is in the form of a pharmaceutically acceptable salt for intravenous use.

10. (Amended) A formulation according to claim 1 for use in the treatment of cancer.

16. (Amended) A product according to claim 14 wherein the chemotherapeutic agent is selected from taxane, taxane derivatives, CPT-11, camptothecin and derivatives thereof, doxorubicin, idarubicin, epirubicin, etoposide, navelbine, vinblastine, carboplatin, cisplatin, Sugan SU 6668 and Sugan SU 5416.

REMARKS

Claims 1-24 are active in the present application. Claims 3-5, 7-8, 10, 16, have been amended to remove multiple dependencies. No new matter is added. An action on the merits and allowance of claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Stefan U. Koschmieder, Ph.D.
Registration No. 50,238



22850

(703) 413-3000
NFO/DJP/smi
I:\atty\SUKOS\220037us-PR.wpd